“As Galera is poised to enter Phase 2 with our unique approach to treating cancer, this is an exciting time,” Beardsley said. “Many cancer patients face a difficult decision between aggressively fighting the disease and continuing in their daily lives, and we believe we can offer the ability to more effectively attack the cancer while lessening the burden of therapy.”
Previously, Beardsley was Chief Executive Officer of Metabolic Solutions Development Company, President and Chief Executive Officer of Kereos, and acting Chief Executive Officer of Metaphore Pharmaceuticals. At each of these he played key roles in successful private equity fundraising rounds, partnering, and clinical development of innovative therapeutic and diagnostic agents. In addition, he is the cofounder and former Managing Member of SImile Investors, LLC. and has held a number of positions with other biotechnology and life science related firms, including bioStrategies Group and Vector Securities International. Beardsley also previously served on the boards of Collagenex Pharmaceuticals, BioSeek and KemPharm.
Beardsley holds a Ph.D. in Biochemical Engineering and a B.S. in Chemical Engineering from the University of Iowa, along with an M.B.A. in Finance from the University of Chicago.
# # #
Galera Therapeutics was founded in 2009 and is headquartered in St. Louis at the Center for Emerging Technologies. Galera is dedicated to the development of innovative, effective and safe medicines to treat cancer and prevent the side effects associated with current treatment regimens. The company’s dismutase mimetics – small molecule enzyme replacement for the body’s ubiquitous superoxide dismutase enzymes – have shown the unprecedented ability to both attack tumors and protect normal tissue from the damage resulting from other cancer treatments, such as radiation therapy, chemotherapy and cytokine immunotherapies such as interleukin-
